Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen – The ANRS CO20-CUPIC study

Abstract : BACKGROUND AND OBJECTIVE: To assess within the ANRS CO20-CUPIC cohort whether the viral load (VL) at week 2/week 6 for telaprevir/boceprevir-based triple therapy, respectively, was predictive of sustained virological response (SVR) in patients with hepatitis C virus (HCV) infection and to study the relevance of this measurement to early diagnose drug resistance. METHODS: Observational study of HCV genotype 1 patients with compensated cirrhosis (Child-Pugh A), non-responders to a prior course of interferon (IFN)-based therapy and who started triple therapy. Patients received either 12 weeks of telaprevir in combination with PEG-IFN/ribavirin (RBV), then 36 weeks of PEG-IFN/RBV, or 4 weeks of PEG-IFN/RBV, then 44 weeks of PEG-IFN/RBV and boceprevir. RESULTS: A total of 262 patients were analyzed. For telaprevir-treated patients, 28% had undetectable VL at W2 of whom 81% achieved SVR12 whereas 67% had undetectable VL at W4 of whom 67% achieved SVR12. For boceprevir-treated patients 20% had undetectable VL at W6 and 86% of them achieved SVR12 whereas 36% had undetectable VL at W8 among whom 73% achieved SVR12. Five telaprevir-treated patients had a VL increase between W2 and W4 after a decrease between D0 and W2. Four of them did not achieve SVR12. Similarly, six boceprevir-treated patients had a VL increase between W6 and W8 after a decrease between D0 and W6. Five did not reach SVR12. CONCLUSIONS: The assessment of HCV RNA level after two weeks of triple therapy in cirrhotic non-responder patients is a good predictor of SVR. This assessment was useful to do an early diagnosis of viral breakthrough.
Type de document :
Article dans une revue
Clinics and Research in Hepatology and Gastroenterology, Elsevier, 2015, 39 (4), pp.443 - 450. 〈10.1016/j.clinre.2014.12.007〉
Liste complète des métadonnées

https://hal.univ-lorraine.fr/hal-01669113
Contributeur : Ngere Ul <>
Soumis le : mercredi 20 décembre 2017 - 15:35:13
Dernière modification le : mardi 11 septembre 2018 - 15:19:04

Identifiants

Citation

François Bailly, Victor Virlogeux, Cécilie Dufour, Pierre Pradat, Christophe Hézode, et al.. Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen – The ANRS CO20-CUPIC study. Clinics and Research in Hepatology and Gastroenterology, Elsevier, 2015, 39 (4), pp.443 - 450. 〈10.1016/j.clinre.2014.12.007〉. 〈hal-01669113〉

Partager

Métriques

Consultations de la notice

82